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Vitamin D Receptor Activation Improves
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Ulrich Zu¨gel5, Magda Babina1, Andreas Radbruch2 and Margitta Worm1
Atopic dermatitis (AD) is a common chronic inflammatory skin disease that has increased in prevalence over the
last several decades in industrialized countries. AD is a multifactorial, heterogenous disease with a variety of
defects in the immune system, in antimicrobial defense mechanisms and epidermal barrier integrity, which
collectively contribute to the risk and severity of AD development. Vitamin D receptor (VDR) signaling has been
shown to be important not only in the immune system but also in the skin and in particular keratinocytes to
regulate skin homeostasis and epidermal barrier function. However, this work aimed to analyze the role and
clinical efficiency of VDR activation by a VDR agonist without calcium-mobilizing activity in a mouse model of
allergen-triggered eczema. We show that the systemic administration of the low-calcemic VDR agonist
significantly improved the allergen-triggered eczema. Thereby, forkhead box P3 (Foxp3)-expressing regulatory
T cells, revealed to have a role in AD, were selectively increased in the skin of VDR agonist-treated mice.
Moreover, our results demonstrate a marked induction of skin barrier gene and antimicrobial peptide gene
expression in skin lesions of VDR agonist-treated mice. Thus, our study provides evidence that systemic VDR
agonist treatment may improve allergen-triggered eczema in vivo.
Journal of Investigative Dermatology (2012) 132, 330–336; doi:10.1038/jid.2011.296; published online 22 September 2011
INTRODUCTION
1a,25-Dihydroxyvitamin D3 (calcitriol), the biologically
active metabolite of vitamin D3, has been identified over
the past decades to have strong immunomodulatory effects by
functioning on cells of the innate and adaptive immune
system (Adams and Hewison, 2008; Mora et al., 2008).
Calcitriol functions primarily by binding to the vitamin D
receptor (VDR), which functions as a ligand-dependent
transcription factor (Bouillon et al., 2008). Liganded VDR
recruits its preferred dimerization partner, the retinoid X
receptor, to form a heterodimer that subsequently binds to
vitamin D response elements in the promoter regions of target
genes. Similarly, calcitriol and VDR effectively regulate
epidermal differentiation and permeability barrier homeo-
stasis (Bikle, 2010).
The prevalence of atopic dermatitis (AD) has increased
over the last decades in industrialized countries, now
affecting around 15–30% of children and 2–10% of adults
(Bieber, 2010). AD is a chronic and relapsing eczematous
skin inflammation associated with epidermal barrier dysfunc-
tion, intense pruritus, and cutaneous hyperreactivity to
environmental triggers (Leung et al., 2004; Bieber, 2008).
By histopathology, AD skin lesions display prominent
infiltrates of mononuclear cells in the dermis combined with
intercellular edema in the epidermis (spongiosis; Bieber,
2008). The exact cause of AD is not well understood, but the
disease is regarded as multifactorial, heterogenous, and
associated with defects of the immune system, in antimicro-
bial defense mechanisms and epidermal barrier integrity
(De Benedetto et al., 2009; Bieber, 2010).
The permeability barrier function is not regulated by the
corneocyte, but rather by the lipid-enriched, extracellular
matrix of the stratum corneum, which is mainly composed of
the structural proteins, loricrin, involucrin, filaggrin (FLG),
and small proline-rich proteins (Scharschmidt et al., 2009).
By cross-linking these and other proteins, transglutaminases
are similarly involved in the formation of the epidermal
barrier (Candi et al., 2005). Recently, loss-of-function
genetic variants of the filaggrin gene (FLG) encoding the
intracellular protein, FLG, have been reported to be strong
predisposing factors for AD (Palmer et al., 2006). FLG
deficiency alone provokes a permeability barrier abnormality
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(Scharschmidt et al., 2009). Other reports showed reduced
expression of antimicrobial peptides, involucrin, and loricrin
in AD skin (De Benedetto et al., 2009).
The importance of VDR signaling for epidermal differ-
entiation and permeability barrier homeostasis has been
shown by in vitro and in vivo studies. For instance, calcitriol
has been reported to increase involucrin and transglutamin-
ase expression in keratinocytes (Su et al., 1994; Bikle et al.,
2001, 2002). Silencing of the VDR and two VDR coactivators
blocked keratinocyte differentiation and decreased the
expression of FLG (Oda et al., 2007). VDR-null mice exhibit
a defect in epidermal differentiation as shown by reduced
levels of involucrin, proFLG, and loricrin, as well as loss of
keratohyalin granules (Xie et al., 2002). In addition, CYP27B1
(1aOHase) (25-hydroxyvitamin D3-1a-hydroxylase)-null ani-
mals, which are unable to produce the biologically active
calcitriol from its precursor 25-hydroxyvitamin D3, show a
reduction in the epidermal differentiation markers involucrin,
FLG, and loricrin and display a markedly delayed recovery of
normal barrier function following disruption of the barrier
(Bikle et al., 2004).
On the basis of these observations, we hypothesized that
specific VDR targeting may represent a therapeutic option for
the treatment of AD. Owing to its major function in calcium
and phosphorus homeostasis, calcitriol itself, however, has
serious side effects (hypercalcaemia, hypercalciuria, and
bone resorption), which hamper its clinical use (van Etten
and Mathieu, 2005). To circumvent this limitation, synthetic
so-called dissociated VDR agonists have been developed.
They maintain or even augment the beneficial immunomod-
ulatory effects but display weak calcium-mobilizing activity.
Here, we wanted to delineate whether VDR activation might
be of therapeutic benefit in the treatment of AD. Therefore,
we used a recently described low-calcemic VDR agonist that
shows profound immunomodulatory activities (Zugel et al.,
2009), in particular with regard to the B-cell-dependent
allergic immune response (Hartmann et al., 2011). We show
that the VDR agonist induces the expression of genes
associated with barrier function and, more importantly,
inhibits the development of allergen-triggered eczema in a
mouse patch test model.
RESULTS
The VDR agonist ameliorates allergen-triggered eczema
By using a VDR agonist that does not induce hypercalcemia
but nevertheless possesses strong immunomodulatory effects
(Zugel et al., 2009), we set out to investigate the influence of
VDR signaling in a defined model of allergen-triggered
eczema (Figure 1). Therefore, mice were sensitized three
times with ovalbumin (OVA) intraperitoneally, followed by
the epicutaneous challenge with OVA. Subsequently, mice
were treated with either the VDR agonist or PBS control,
starting after removal of the first patch to have a therapeutic
setting regarding the epicutaneous sensitization. VDR activa-
tion by the agonist led to a clear improvement in all clinical
signs of the OVA-triggered eczematous response, namely
erythema, edema, excoriation, dryness, and extension. Thus,
VDR agonist treatment reduced the clinical skin score from
10.0±1.5 to 7.4±2.4 (Figure 2). Taken together, treatment
with the low-calcemic VDR agonist leads to a significant
improvement of the allergen-triggered eczematous response.
VDR activation does not significantly alter local T-cell
infiltration
Immunohistochemistry was performed to analyze the relative
distribution of T-cell subsets in lesional skin. As shown in
BALB/c, 10-week-old
Sensitization with
OVA/alum (i.p.) VDR agonist or vehicle (i.p.)
Days 0 14 21 24 28 42
Sensitization with OVA/alum (e.c.)
45 49 63 66 70 71
Analysis
Figure 1. Experimental setup for ovalbumin (OVA) sensitization and vitamin D receptor (VDR) agonist treatment. Mice were sensitized intraperitoneally (i.p.)
and epicutaneously (e.c.) as described in Materials and Methods. Treatment with VDR agonist or control started upon removal of the first patch (light gray
arrows). On day 71, mice were killed and skin samples collected.
15 *
10
5
0
Control VDR agonist
Cl
in
ica
l s
kin
 s
co
re
Figure 2. The vitamin D receptor (VDR) agonist inhibits allergen-triggered
skin eczema. Mice were sensitized and treated with the VDR agonist or
control as described in Figure 1 and Materials and Methods. On day 71, mice
were killed and the severity of the eczema was evaluated as described in
Materials and Methods. The index of severity (clinical skin score) is shown as
mean±SD for each group (nX9; *Po0.05). One representative picture of
each group is shown.
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Figure 3a, there was no significant alteration between VDR
agonist-treated and control mice in terms of total CD4þ
T cells. Nevertheless, a tendency of higher CD4þ T-cell
numbers was observed in the VDR ligand-treated group
(VDR agonist: 566.5±128.9 cells per mm2; control mice:
427.9±249.7 cells per mm2; P¼0.1628; corresponding to a
1.3-fold increase). Conversely, there was a slight tendency of
CD8þ T cells to decrease in the skin of VDR agonist-treated
mice, but this did not reach statistical significance (Figure 3b).
Taken together, overall T-cell skin infiltrates remain stable
upon VDR activation despite the clinical improvement in the
signs of eczematous response.
The VDR agonist specifically increases Foxp3þ cells in skin
lesions
The above data implied that total CD4þ T-cell numbers in
skin lesions were not decreased upon VDR activation, but
rather showed the opposite tendency, and that this occurred
simultaneously with an improvement of clinical signs. The
CD4þ cell compartment comprises a heterogenous group of
T cells, including the T helper (TH), T effector (Teff), and the
regulatory T-cell subset, the latter being forkhead box P3
(Foxp3) positive (Zhu and Paul, 2010). We therefore analyzed
the density of Foxp3þ cells in lesional skin. It was found that
there was indeed a clear-cut increase in the number of
Foxp3þ cells by 33.9% upon treatment with the VDR agonist
(VDR agonist: 193.7±38.6 cells per mm2; control:
144.7±43.2 cells per mm2; P¼0.026; Figure 4a), which
might explain the increase in infiltrating CD4þ T cells (Figure
3a). The increase in Foxp3þ cells was confirmed by a 2.0-
fold increased expression of Foxp3 mRNA in the skin of VDR
agonist-treated mice (VDR agonist: 2.59±1.01 arbitrary unit
(AU); control: 1.28±0.91 AU; P¼0.0148; Figure 4b). As
Foxp3þ regulatory cells function by dampening responses of
Teff, and both TH1 and TH2 subsets, we also analyzed the skin
sections for its TH1 and TH2 signature cytokine expression.
The VDR agonist reduced Il4 expression in lesional skin by
32.2% (VDR agonist: 0.63±0.26 AU; control: 0.93±0.30
AU; P¼0.0435; Figure 4c). In addition, Ifng expression was
reduced by 41.8%, but this did not reach statistical
significance (VDR agonist: 0.12±0.07 AU; control:
0.20±0.13 AU; P¼ 0.0749; Figure 4d). Taken together,
these data show that Foxp3þ cells are selectively increased
in the skin after VDR activation.
VDR activation induces barrier and antimicrobial peptide gene
expression
VDR ligands are known to induce genes important for skin
barrier function (Bikle, 2010), the impairment of which is a
hallmark of AD pathogenesis (Cork et al., 2009). We
therefore determined whether the VDR agonist may induce
barrier and antimicrobial gene expression in lesional skin.
The treatment with the VDR agonist indeed resulted in a
robust induction of several skin barrier genes, including
loricrin (Lor), involucrin (Ivl), transglutaminase 1 (Tgm1), and
filaggrin (Flg), and, moreover, the antimicrobial peptide
b-defensin 2 (Defb2) and, to a lesser degree, b-defensin 3
(Defb3; Figure 5). The highest induction of gene expression
with about 6.1-fold was found for loricrin (P¼ 0.0003) and
transglutaminase 1 (4.6-fold, Po0.0001; Figure 5a and c).
The induction of FLG (Figure 5d) and involucrin (Figure 5b)
by VDR treatment was 3.3-fold (Po0.0001) and 4.4-fold
(Po0.0001), respectively. The expression of b-defensin
2 was 4.1-fold (P¼0.0006, Figure 5e) and b-defensin 3
was 0.2-fold (P¼ 0.0464, Figure 5f) increased by the VDR
agonist compared with the control. Taken together,
these data show that VDR ligation induces the expression
of skin barrier and antimicrobial peptide genes in eczematous
skin lesions.
DISCUSSION
We report here that systemic low-calcemic VDR agonist
treatment ameliorates allergen-triggered eczema in mice, a
model closely reflecting AD in humans. This study was
prompted by our recent observation that the low-calcemic
VDR agonist ZK203278 dampens B-cell-dependent allergic
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Figure 3. CD4þ and CD8þ cells in skin lesions of ovalbumin (OVA)-sensitized and vitamin D receptor (VDR) ligand-treated mice. CD4þ (a) and CD8þ
(b) T cells were stained and quantified in the dermis of lesional skin of VDR agonist-treated and control mice. Numbers of cells per mm2 are shown as
mean±SD for each group (nX9). One representative photograph of each group is shown; NS, not significant. Bar¼ 100mm.
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immune responses in vitro and in vivo (Hartmann et al.,
2011), as well as by reports about its role in keratinocyte
differentiation (Bikle, 2004, 2010). In fact, a clear-cut
improvement in the signs of the eczematous response, as
summarized in the clinical skin score, was detected upon
treatment with the VDR agonist.
Dermal CD4þ T-cell infiltration is critical for the
development of AD skin lesions (Oyoshi et al., 2009).
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Figure 4. The vitamin D receptor (VDR) agonist increases the number of Foxp3þ cells in lesional skin. (a) Foxp3þ cells were stained and quantified
in the dermis of lesional skin of VDR agonist-treated and control mice. Numbers of cells per mm2 are shown as mean±SD for each group (nX8; *Po0.05).
One representative photograph of each group is shown; bar¼100 mm. Expression levels of Foxp3 (b), Il4 (c), and Ifng (d) in lesional skin of each group
were assessed by quantitative PCR. Shown is the relative expression of the target gene compared with the housekeeping gene Hprt in arbitrary units
(AU; nX8; *Po0.05). The arrows in panels a and b denote the Foxp3þ cells.
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Figure 5. Systemically applied vitamin D receptor (VDR) agonist induces barrier and antimicrobial genes in lesional skin. Expression levels of skin
barrier genes and antimicrobial peptides in lesional skin were analyzed by quantitative PCR. The relative expression of loricrin (Lor, a), involucrin
(Ivl, b), transglutaminase 1 (Tgm1, c), filaggrin (Flg, d), b-defensin 2 (Defb2, e), and b-defensin 3 (Defb3, f) was measured in comparison with the
housekeeping gene Hprt and is shown as mean±SD for each group (nX8; *Po0.05, ***Po0.001).
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By analyzing VDR-mediated cellular changes, we were able
to observe a minor increase in the number of infiltrating
CD4þ T cells upon VDR activation, simultaneously with an
improvement of the skin. We therefore reasoned that the VDR
agonist might have altered the composition of CD4þ
T-cell subsets in the skin. TH cells consist of several subsets,
each of which impact immune responses in a unique manner
(Zhu and Paul, 2010). Natural CD4þ CD25þ Foxp3þ
regulatory T cells (Tregs), which comprise 5–10% and 1–2%
of the CD4þ T-cell pool in mice and humans, respectively
(Ghoreishi et al., 2009), and other subtypes of induced Treg
cells inhibit both TH1- and TH2-cell function by reducing
their cytokine production and by direct interaction with
effector T cells (Beissert et al., 2006). Treg cells are crucial for
the maintenance of skin immune homeostasis (Dudda et al.,
2008), and their number is strongly decreased in inflamma-
tory skin diseases, including AD and psoriasis (Verhagen
et al., 2006). In the present study, we found increased
numbers of Foxp3þ cells in VDR agonist-treated mice and
this was associated with reduced expression of Il4 and Ifng in
the skin. The importance of VDR signaling for proper Treg
function in the skin is underlined by the finding that VDR-
knockout mice fail to increase Foxp3þ Tregs in skin-draining
lymph nodes following UV irradiation (Ghoreishi et al.,
2009). There is other robust evidence for a crucial role of the
VDR for Treg generation, maintenance, and function. For
example, a combination of calcitriol and dexamethasone or
calcitriol alone has been shown to induce CD4þ T cells to
differentiate in vitro into Treg cells, even in the absence of
antigen-presenting cells (Barrat et al., 2002; O’Garra and
Barrat, 2003; Jeffery et al., 2009). Moreover, topical calcitriol
or calcipotriol treatment was shown to enhance the
suppressive activity of Tregs in skin-draining lymph nodes,
whereas calcipotriol caused the expansion of antigen-specific
Treg cells (Gorman et al., 2007; Ghoreishi et al., 2009). Taken
together, the enhanced suppressive Treg function likely
contributes to the VDR-mediated improvement of allergen-
triggered eczema.
Li et al. (2006) reported that topical treatment with
calcitriol and MC903 (a VDR agonist) induces thymic stromal
lymphopoietin and triggers an AD-like phenotype. In their
model, topical application of 0.1–0.17mg calcitriol was
applied per ear. In the current study, only 0.15mg of the
VDR agonist was applied systemically via intraperitoneal
injections. Thus, it cannot be assumed that high local
concentration as in the study by Li et al. was achieved in
our setting. However, we observed an increase in Tslp
expression in skin samples from mice that were systemically
treated with the VDR agonist (Supplementary Figure S1
online). In contrast, we did not observe an aggravation of
skin eczema in these mice, which may result from counter-
regulating mechanisms, in particular by similar effects on skin
barrier gene expression and regulatory T cells. In addition,
topically applied calcitriol and analogs represent successful
therapeutic approaches in psoriasis (Sigmon et al., 2009).
In fact, calcitriol at 3mg g1 ointment was found to be a safe
and effective treatment for mild-to-moderate psoriasis with
only mild local adverse effects in a small number of patients
(Sigmon et al., 2009). Clearly, psoriasis patients treated with
VDR agonists do not normally develop AD or AD-like lesions.
Conversely, it is now well recognized that psoriasis and AD
share many features, despite evident differences, and are more
strongly related than previously suspected. For example, both
display mutations in partially common genes and are
characterized by dysregulated T-cell responses and profound
barrier defects (Bieber, 2008, 2010; De Benedetto et al., 2009;
Nestle et al., 2009; Roberson and Bowcock, 2010). The
correct formation and function of the epidermal barrier are
ensured by the expression of proteins such as FLG, involucrin,
loricrin, and transglutaminases, and a complex series of lipids
(Candi et al., 2005). Perturbed barrier function in AD has been
reported in mouse and man. For example, NC/Nga mice, a
spontaneous mouse model of AD, show skin barrier
abnormalities under conventional conditions (Aioi et al.,
2001). Flaky tail mice (ft/ft) are characterized by dry, flaky skin
associated with increased transepidermal water loss, as
observed in patients with AD and FLG mutations (Presland
et al., 2000; Kezic et al., 2008). In addition, loss-of-function
genetic variants of the FLG gene have been reported to be
strong predisposing factors for AD (Palmer et al., 2006;
Weidinger et al., 2006; O’Regan and Irvine, 2008), whereas
others showed a reduced expression of antimicrobial pep-
tides, involucrin, and loricrin in AD skin (Kim et al., 2008; De
Benedetto et al., 2009). We have found that VDR activation
clearly improved the signs of allergen-triggered eczema,
simultaneously with a strong increase in the expression of
genes important for the permeability barrier function such as
FLG, loricrin, involucrin, and transglutamin-
ase I, but also of the antimicrobial peptides b-defensin 2
and 3. This is in line with previous reports showing a direct
increase in involucrin and transglutaminase expression by
VDR activation in keratinocytes (Su et al., 1994; Bikle et al.,
2001, 2002). Similarly, silencing of the VDR and VDR
coactivators led to decreased FLG expression and subse-
quently decreased keratinocyte differentiation (Oda et al.,
2007). Moreover, data from VDR/ and CYP27B1/
(1aOHase/) mice exhibit a defect in epidermal differentia-
tion as shown by reduced levels of involucrin, FLG, and
loricrin (Xie et al., 2002; Bikle et al., 2004). In accordance
with previous reports showing the crucial role of IL-4 for
regulating epidermal homeostasis and innate barrier function
(Kim et al., 2008; Sehra et al., 2010), reduced Il4 expression as
observed in VDR agonist-treated mice may have contributed
to the upregulation of genes forming the cornified envelope.
In addition, Hong et al. (2008) have shown increased mouse
b-defensin 2 and 3 expression at both the mRNA and protein
level after 3 days of UVB exposure in parallel with a beneficial
effect on permeability barrier function, which depends, at
least in part, on activation of the cutaneous vitamin D system.
Importantly, Cyp24a1 expression, the most sensitive indicator
for VDR activation (Schuster, 2011), was shown to be
markedly increased in mouse skin between 4 and 6hours
after intraperitoneal administration with a pharmacological
dose of calcitriol (Akeno et al., 1997).
Taken together, our study has provided evidence that
systemic low-dose treatment with a low-calcemic VDR
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agonist may improve allergen-induced eczema in vivo,
which to our knowledge has not been previously reported.
Therefore, targeting the VDR with low-calcemic agonists may
develop into a feasible treatment option for AD. Future
studies in humans will be required to assess the full potential
of VDR-targeted therapies for AD management.
MATERIALS AND METHODS
Mice and treatments
Female, 10-week-old BALB/c mice (Federal Institute of Risk
Assessment, Berlin, Germany) were maintained in a patho-
gen-free environment under laboratory conditions with
mouse chow and water available ad libitum. All experimental
procedures were performed in compliance with protocols
approved by the local State Office of Health and Social
Affairs. Mice were sensitized intraperitoneally using 10 mg
OVA (Sigma-Aldrich, Steinheim, Germany) adsorbed to
1.5mg aluminum hydroxide and magnesium hydroxide
(Imject Alum, Thermo Fisher Scientific, Schwerte, Germany)
in a total volume of 100ml on day 1, 14, and 21 (Figure 1).
For the induction of AD skin lesions, the epicutaneous
allergen application patch test was used (Dahten et al., 2008);
the scheme is depicted in Figure 1. Mice were shaved on
the ventral side with a wet razor. A measure of 100 mg OVA
(Sigma-Aldrich) adsorbed to 1.5mg aluminum hydroxide and
magnesium hydroxide (Imject Alum, Thermo Fisher Scien-
tific) in a total volume of 20 ml was applied to a sterile patch
and secured to the skin with an elastic cohesive bandage. The
patch was placed for three 1-week periods (with patch
renewal after 3 days) separated by a 2-week interval between
each application. ZK203278 (hereinafter referred to as VDR
agonist; 6 mg kg1 per day in PBS/0.03% ethanol) or an equal
volume of PBS/0.03% ethanol as control was injected intra-
peritoneally for two consecutive 5-day periods separated by a
2-day-break after the first and second patch (Figure 1).
Assessment of allergen-triggered eczema
Erythema, edema, excoriation, dryness, and extension were
used as typical hallmarks of human AD to evaluate clinical
severity as described previously (Dahten et al., 2008; Babina
et al., 2010). Each parameter was evaluated independently
and blindly by six investigators. Severity was rated according
to scores as follows: 0, no reaction observed; 1, mild signs; 2,
intermediate signs; 3, severe signs. The total score was taken
as the index of severity (clinical skin score).
Immunohistochemistry
Sections of 5 mm were prepared and used for staining by the
streptavidin–biotin complex system as described previously
(Babina et al., 2010). Briefly, sections were blocked with 10%
normal goat serum (Dako, Hamburg, Germany) and the
avidin/biotin blocking kit (Vector Peterborough, Cambridge-
shire, UK), and then incubated with rat anti-mouse CD4
(RM4–5) or CD8 (53-6.7) followed by incubation with
biotinylated goat anti-rat IgG (all from BD Pharmingen,
Heidelberg, Germany). Negative controls were run in parallel
omitting either the primary or the secondary antibody. Signals
were detected by the alkaline phosphatase/red detection kit
and by hematoxylin counter staining. Foxp3þ cells were
stained as described (Heimesaat et al., 2007). In all cases,
positively stained cells were counted at a 100 magnifica-
tion in 3–6 fields of 200 200mm2, and are expressed as
mean cell number per mouse normalized to 1mm2.
RNA isolation from skin samples
Samples from lesional skin (5 mm) were collected with a
punch biopsy and frozen instantly in liquid nitrogen, and
stored at 80 1C. Samples were homogenized by pounding
in a mortar in liquid nitrogen. Homogenized samples were
subjected to proteinase K (Macherey-Nagel, Du¨ren, Germany)
digestion for 10minutes at 55 1C. For RNA isolation, the
RNeasy Mini Kit (Qiagen, Hilden, Germany) was used accor-
ding to the manufacturer’s protocol with an additional step of
DNase (Macherey-Nagel) digestion for 15minutes at room
temperature. The quality of the RNA samples was assessed by
agarose gel electrophoresis upon ethidium bromide staining
(Sigma-Aldrich, Steinheim, Germany).
Reverse transcription and quantitative PCR
RNA was reverse transcribed with TaqMan reverse transcrip-
tion reagents (Applied Biosystems, Darmstadt, Germany) and
quantitative PCR performed with the Fast Start DNA Master
SYBR Green I and LightCycler 1.5 (Roche Diagnostics,
Mannheim, Germany) according to the manufacturer’s
protocol. Oligonucleotide primers were synthesized by TIB
MOLBIOL (Berlin, Germany) and are listed in Supplementary
Table S1 online. The expression levels of target gene mRNA
were quantified relative to the expression of the reference
gene Hprt. Relative gene expression was calculated by the
comparative DCT method as described (Schmittgen and
Livak, 2008).
Data analysis
Data were analyzed using the statistical program GraphPad
Prism (GraphPad Software) by applying an appropriate test
(unpaired t-test or non-parametric Mann–Whitney U-test
when data were not normally distributed). Data are shown
as mean±SD. Significance between experimental and
control mice was assumed at Po0.05 for all tests.
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